Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CelTOS monoclonal antibodies
- Development stage
- Preclinical
- Lead developer
- National Institutes of Health
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Anti-CelTOS monoclonal antibodies are preclinical-stage therapeutic candidates being investigated for the prevention and transmission-blocking of malaria. These antibodies target the cell-traversal protein for ookinetes and sporozoites (CelTOS), a highly conserved antigen across *Plasmodium* species that is essential for parasite cell traversal in both the mammalian host and the mosquito vector. Developed by researchers at the National Institutes of Health (NIH) and the University of South Florida (USF), specific monoclonal antibodies such as 7g7 and 4h12 have demonstrated multistage, cross-species sterile protection. They inhibit CelTOS-mediated pore formation and membrane disruption, thereby preventing liver infection in the host and blocking parasite transmission to mosquitoes.
- Other names
- 3C34D104h127g7anti-CelTOS mAbsanti-CelTOS monoclonal antibodyCelTOS-specific monoclonal antibodies
02
Targets
CelTOS (Cell-traversal protein for ookinetes and sporozoites)
Beyond the preview
Go deeper on anti-CelTOS monoclonal antibodies.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CelTOS monoclonal antibodies.